Arch Biopartners Inc., of Toronto, said it closed the nonbrokered, unsecured convertible note financing for gross proceeds of CA$500,000 (US$376,779). The company will primarily use proceeds to fund final preclinical tasks for Metablok and the initial costs of the phase I trial.